Endotoxin-induced suppression of pulmonary antibacterial defenses against Staphylococcus aureus.
In order to evaluate the effect of endotoxin on lung host defenses, Sprague-Dawley rats were intravenously injected with either placebo or 5 mg/kg of Escherichia coli lipopolysaccharide B. Two hours after treatment, animals were challenged with Staphylococcus aureus by either low dose aerosol inhalation or high dose intratracheal instillation of the bacteria into the lungs. Quantitative lung bacteriologic examination and bronchoalveolar lavage (BAL) for total and differential cell counts were performed immediately (zero hour) and at 4 h after bacterial challenge. Lung phagocytic defenses against aerosolized S. aureus challenges are provided solely by the alveolar macrophage (AM) in the absence of inflammation. In aerosol-challenged control rats, 20.6 +/- 2.0% of the initial deposited bacterial challenge remained viable in the lung at 4 h. Animals pretreated with endotoxin, however, showed a significant decrease in pulmonary bactericidal activity (31.3 +/- 3.4% bacteria remaining at 4 h), indicating a defect in alveolar macrophage (AM) function. Further assessment of the bactericidal oxidative metabolism of endotoxin-treated AM by luminol-enhanced chemiluminescence indicated an increased production of free radical oxygen species when compared with control nontreated cells in both the unstimulated (66 +/- 4 versus 38 +/- 7 x 10(3) cpm in control) and stimulated (250.5 +/- 17.1 versus 147.1 +/- 6.2 x 10(3) cpm in control) states. Total and differential cell counts in both control and endotoxin-treated aerosol-challenged rats were similar.(ABSTRACT TRUNCATED AT 250 WORDS)
Harris
S E
SE
Department of Pulmonary/Critical Care Medicine, Louisiana State University Medical Center, New Orleans 70112.
Nelson
S
S
Astry
C L
CL
Bainton
B G
BG
Summer
W R
WR
D000336:Aerosols; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D015169:Colony Count, Microbial; D004731:Endotoxins / Q000008:administration & dosage / Q000494:pharmacology*; D004926:Escherichia coli; D008168:Lung / Q000187:drug effects / Q000502:physiology*; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D008297:Male; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D010084:Oxidation-Reduction; D011650:Pulmonary Alveoli / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D013211:Staphylococcus aureus / Q000302:isolation & purification / Q000502:physiology*; D014132:Trachea / Q000382:microbiology
D000336:Aerosols; D004731:Endotoxins